Dermatology Enrollment Form
Medications A-M

Please fax the completed form to:

888-842-3977

Signature Care Program

6040 Tarbell Road
Syracuse, NY 13206
Phone: 888-843-2040
Fax: 888-842-3977
www.noblehealthservices.com

Delivery Need By: Delivery to: ☐Patients Home ☐Physician's Office ☐Other

PATIENT INFORMATION	PRESCRIBER INFORMATION
Patient Name: ☐Female ☐Male	Prescriber Name:
Address:	Address:
City, State, Zip: , ,	City, State, Zip: , ,
Phone:	Phone:
Date of Birth:	Fax:
Social Security Number:	DEA/NPI#:

INSURANCE – PLEASE FAX COPY OF PRESCRIPTION CARD FRONT & BACK

CLINICAL INFORMATION

Diagnosis: ☐ Atopic Dermatitis L20 ☐ Psoriasis L40 ☐ Psoriatic arthritis L40.5 ☐Hidradenitis Suppurativa L73.2 ☐ Other	Has the patient been treated previously for this condition? ☐ Yes ☐ No
Last PPD Test D/M/Y ☐ Positive ☐ Negative Date: / /	Medications failed:
Height: feet inches Weight: lbs.	Medications on:
Allergies:	Other notes:

PRESCRIPTION INFORMATION

Medication:	Dosage/Strength:	Directions:		Quantity:	Refills:
Actemra®	☐ 162mg/0.9ml	☐ SC every OTHER week ☐ SC every week ☐ Other:		☐ 4 week supply ☐ Other:	
Cimzia®	☐ 200mg/ml Prefilled SYR ☐ Starter Kit	Loading Dose: ☐ Inject 400mg SC at weeks 0,2 and 4	Maintenance Dose: ☐ 200mg SC every other week ☐ 400mg SC every 4 weeks	☐ 4 week supply	
Cosentyx® **Enhanced Specialty Pharmacy Program Participant*	☐ 150mg Pen ☐ 150mg SYR	Loading Dose: ☐ 150mg 0,1,2,3,4 weeks ☐ 300mg 0,1,2,3,4 weeks	Maintenance Dose: ☐ 150mg every 4 weeks ☐ 300mg every 4 weeks	☐ 4 week supply (maintenance) ☐ 5 week supply (loading) ☐ Other:	
Cosentyx® **Enhanced Specialty Pharmacy Program Participant* *Covered Until You're Covered*	☐ 150mg Pen ☐ 150mg Syringe	Loading Dose: ☐ 150mg 0,1,2,3,4 weeks ☐ 300mg 0,1,2,3,4 weeks	Maintenance Dose: ☐ 150mg every 4 weeks ☐ 300mg every 4 weeks	☐ 4 week supply (maintenance) ☐ 5 week supply (loading) ☐ Other:	
Dupixent®	☐ 300mg/ml Prefilled SYR	Loading Dose: ☐ Inject two 300mg SC once	Maintenance Dose: ☐ Inject 300mg every other week	☐ 4 week supply (maintenance) ☐ 5 week supply (loading) ☐ Other:	
Enbrel®	☐ 50mg/ml Single Use Prefilled SYR ☐ 50mg/ml SureClick AutoInjector ☐ 25mg/0.5ml Prefilled SYR ☐ 25mg Vial	☐ Inject 50mg SC TWICE a week (72-96 hours apart) ☐ Inject 50mg SC ONCE a week ☐ Inject 25mg SC TWICE a week (72-96 hours apart) ☐ Other:		☐ 4 week supply ☐ Other:	
Humira®	☐ 40mg/0.8ml Pen ☐ 40mg/0.8ml Prefilled SYR	☐ Inject 40mg SC every OTHER week ☐ Inject 40mg SC ONCE a week		☐ 4 week supply ☐ Other:	
Humira HS	☐ 40mg/0.8ml Pen ☐ 40mg/0.8ml Prefilled SYR	Loading Dose: ☐ Inject 160 mg day 1, 80 mg day 15, maintenance beginning on day 29	Maintenance Dose: ☐ Inject 40 mg SC once weekly	☐ 4 week supply ☐ Other:	
Humira Psoriasis	☐ 40mg/0.8ml Pen ☐ 40mg/0.8ml Prefilled SYR	Loading Dose: ☐ Inject 80 mg SC day 1, 40 mg day 8, 40mg day 22	Maintenance Dose: ☐ Inject 40mg SC every other week	☐ 4 week supply ☐ Other:	

☐ Patient is interested in patient support programs ☐ Ancillary supplies provided for administration

Physician Signature: ___________________________ Date: ____________

E-Scribe Rx and Fax this Form to 888-842-3977

Important Notice: *This communication contains information that is confidential and protected from disclosure. If the reader of this message is not the intended recipient, employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please reply to the sender that you have received the message in error and destroy this copy.*

Dermatology Enrollment Form
Medications N-Z

Please fax the completed form to:

888-842-3977

Signature Care Program

6040 Tarbell Road
Syracuse, NY 13206
Phone: 888-843-2040
Fax: 888-842-3977
www.noblehealthservices.com

Delivery Need By: Delivery to: ☐ Patients Home ☐ Physician's Office ☐ Other

PATIENT INFORMATION	PRESCRIBER INFORMATION
Patient Name: ☐ Female ☐ Male	Prescriber Name:
Address:	Address:
City, State, Zip: , ,	City, State, Zip: , ,
Phone:	Phone:
Date of Birth:	Fax:
Social Security Number:	DEA/NPI#:

INSURANCE – PLEASE FAX COPY OF PRESCRIPTION CARD FRONT & BACK

CLINICAL INFORMATION

Diagnosis: ☐ Atopic Dermatitis L20 ☐ Psoriasis L40 ☐ Psoriatic arthritis L40.5 ☐ Hidradenitis Suppurativa L73.2 ☐ Other	Has the patient been treated previously for this condition? ☐ Yes ☐ No
Last PPD Test D/M/Y ☐ Positive ☐ Negative Date: / /	Medications failed:
Height: feet inches Weight: lbs.	Medications on:
Allergies:	Other notes:

PRESCRIPTION INFORMATION

Medication:	Dosage/Strength:	Directions:	Quantity:	Refills:
Otezla®	☐ 28 day starter pack titration ☐ 30mg	☐ Initial dosage titration per starter pack ☐ 30mg twice daily taken orally	☐ 1 month starter pack ☐ Bottle of 60 ☐ Other:	
Simponi®	☐ 100mg/1ml SmartJect AutoInjector ☐ 100mg/1ml Prefilled SYR ☐ 50mg/0.5ml SmartJect AutoInjector ☐ 50mg/0.5ml Prefilled SYR	☐ Inject 100mg SC ONCE a month ☐ Inject 50mg SC ONCE a month	☐ 4 week supply ☐ Other:	
Siliq™	☐ 210mg/1.5ml Prefilled SYR	☐ Inject 210mg SC at weeks: 0, 1 and 2 and 210mg SC every 2 weeks thereafter	☐ Starter Dose (3 SYR) ☐ Maintenance Dose (2 SYR)	
Stelara®	☐ 45mg/0.5ml Prefilled SYR ☐ 90mg/ml Prefilled SYR	☐ Inject 45mg SC at 0 and 4 weeks, then every 12 weeks thereafter ☐ Inject 90mg SC at 0 and 4 weeks, then every 12 weeks thereafter	☐ 2 SYR loading ☐ 1 SYR maintenance	
Tremfya®	☐ 100mg/ml Prefilled SYR	☐ Inject mg at weeks 0, 4, then every 8 weeks thereafter	☐ Loading Dose/ 4 week supply ☐ Maintenance/ 8 week supply	
Other:				

☐ Patient is interested in patient support programs

☐ Ancillary supplies provided for administration

Physician Signature: ____________________________ Date: _____________

E-Scribe Rx and Fax this Form to 888-842-3977

Important Notice: *This communication contains information that is confidential and protected from disclosure. If the reader of this message is not the intended recipient, employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please reply to the sender that you have received the message in error and destroy this copy.*